Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones

Juan Pablo Maianti, Amanda McFedries, Zachariah H. Foda, Ralph E. Kleiner, Xiu Quan Du, Malcolm A. Leissring, Wei-Jen Tang, Maureen J. Charron, Markus A. Seeliger, Alan Saghatelian () and David R. Liu ()
Additional contact information
Juan Pablo Maianti: Harvard University
Amanda McFedries: Harvard University
Zachariah H. Foda: Stony Brook University
Ralph E. Kleiner: Harvard University
Xiu Quan Du: Albert Einstein College of Medicine
Malcolm A. Leissring: Institute for Memory Impairments and Neurological Disorders, University of California
Wei-Jen Tang: University of Chicago
Maureen J. Charron: Albert Einstein College of Medicine
Markus A. Seeliger: Stony Brook University
Alan Saghatelian: Harvard University
David R. Liu: Harvard University

Nature, 2014, vol. 511, issue 7507, 94-98

Abstract: The discovery of a selective, physiologically active inhibitor of insulin-degrading enzyme (IDE) illuminates the therapeutic potential of IDE inhibitors for the treatment of diabetes and reveals that IDE regulates in vivo glucagon and amylin, in addition to insulin.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature13297 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:511:y:2014:i:7507:d:10.1038_nature13297

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature13297

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().